Showing results (531-540 of 701) with videos related to

Sort By:
Pageof 71
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
Clinical Kidney Journal|April 23, 2024
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY populationNavdeep Tangri, Thomas Ferguson, Silvia J Leon, et al.
Diabetes, Obesity & Metabolism|April 24, 2026
Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY AnalysisJoão Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, et al.
Diabetes Care|August 16, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Diabetologia|February 1, 2025
Birthweight and risk of chronic kidney disease after a type 2 diabetes diagnosis in the DD2 cohortAleksander L Hansen, Christian F Christiansen, Charlotte Brøns, et al.
Kidney Medicine|September 27, 2023
Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFRYeli Wang, Ogechi M Adingwupu, Michael G Shlipak, et al.
Kidney International Reports|January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyPeter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Lancet (London, England)|September 28, 2012
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysisBakhtawar K Mahmoodi, Kunihiro Matsushita, Mark Woodward, et al.
Diabetes, Obesity & Metabolism|February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baselineJanet B McGill, Rajiv Agarwal, Stefan D Anker, et al.
BMJ Open|December 16, 2025
Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?Kristian Løkke Funck, Britt Borregaard, Kenneth Egstrup, et al.
Pageof 71